Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 626 of 5804
-
Liver-targeted chemo may boost survival in bile duct cancer
Disease control CompletedPrognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor results for ICC patients. However, Hepatic Arterial I…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising combo tackles rare blood cancer in chinese patients
Disease control OngoingThis study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL. The main aims of the study are to evaluate: * Side effect from the A+CHP * Check how much A+CHP stays in their blood over time. This will help Takeda to work o…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Nasal spray shows promise for depression that Won't quit
Symptom relief Recruiting nowAn open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive…
Phase: PHASE2 • Sponsor: Beckley Psytech Limited • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control Recruiting nowPhase Ib: To observe the safety and tolerability of SI-B001+SI-B003 in combination and to identify RP2D in locally advanced or metastatic head and neck squamous cell carcinoma indications. Initial efficacy, pharmacokinetic characteristics and immunogenicity were evaluated. Phase …
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Gene-Silencing drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Peanut allergy vaccine? new peptide therapy aims to protect kids
Disease control OngoingThe overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Phase: PHASE2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for rare lung cancer mutations: targeted pill tested after surgery
Disease control OngoingThis is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail aims to shrink advanced kidney tumors
Disease control OngoingTo learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a single drug free PMR patients from steroids?
Disease control OngoingPolymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs pl…
Phase: PHASE3 • Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingA clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newl…
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug cocktail could rival standard bladder cancer therapy in major trial
Disease control OngoingThe study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug aims to outsmart resistant colorectal cancer
Disease control OngoingKEYNOTE-177 is currently the only randomized controlled phase III clinical trial evaluating the efficacy and safety of pembrolizumab versus standard chemotherapy combined with targeted first-line therapy for dMMR/MSI-H metastatic colorectal cancer. The study was conducted at 192 …
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New valve replacement offers hope for heart leak patients who can't have standard surgery
Disease control Recruiting nowEvaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local …
Phase: NA • Sponsor: Medtronic Cardiovascular • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New antibody aims to block muscle wasting in rare disease
Disease control OngoingThe purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy join forces against hard-to-treat liver cancer
Disease control TerminatedThe goal of this clinical trial is to evaluate the added value of 166Holmium SIRT to Atezolizumab-Bevacizumab in patients with non resectable HCC. The primary endpoint is the Best Objective Response Rate at 6 months after 166Holmium SIRT according to mRECIST. Participants will b…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Ultrasound 'Key' may let chemo reach Kids' brain tumors
Disease control Recruiting nowPurpose : the aim of this study is to assess the feasibility and safety of ultrasound-induced opening of the blood-brain barrier (BBB) with the SonoCloud-9 implantable ultrasound device in pediatric patients treated for a recurrent malignant supra-tentorial brain tumor treated wi…
Phase: PHASE1 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise for Hard-to-Treat gynecological cancers
Disease control Recruiting nowThe purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gyn…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can baking soda save lives during cardiac arrest?
Disease control OngoingThis is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of sodium bicarbonate during adult in-hospital cardiac arrest. There will be 22 enrolling sites in Denmark. 778 adult patients with in-hospital cardiac …
Phase: PHASE4 • Sponsor: Lars Wiuff Andersen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New trial aims to boost survival in kids with rare lymphoma
Disease control Recruiting nowT-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%\~85%. Two different MTX intensification strategies are used commonly: HD-MTX…
Phase: PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Brain-Zap timed to your waves may boost stroke recovery
Symptom relief Recruiting nowWe will investigate the therapeutic efficacy of EEG-synchronized noninvasive repetitive transcranial magnetic stimulation (rTMS) in the early subacute phase after ischemic stroke to improve upper limb motor rehabilitation. We hypothesize that synchronization of rTMS with the phas…
Phase: NA • Sponsor: University Hospital Tuebingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC